Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This study examined whether palbociclib and cetuximab prolonged overall survival (OS) versus placebo and cetuximab.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Oral Oncol

Title: Oral oncology

Publisher: Elsevier BV

ISSN (Electronic): 1879-0593

ISSN (Print): 1368-8375

Publication date (Electronic): April 2021

Volume: 115

Affiliations

[1 ] Division of Medical Oncology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: dadkins@wustl.edu.

[2 ] Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan.

[3 ] Infusion Center, University of California San Diego Moores Cancer Center, La Jolla, CA, USA.

[4 ] Division of Medical Oncology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.

[5 ] Department of Microsurgery of Otolaryngology Organs, Ivano-Frankivsk Regional Clinical Hospital, Ukraine.

[6 ] Division of Haemtology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

[7 ] Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.

[8 ] Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.

[9 ] Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.

[10 ] Global Product Development-Oncology, Pfizer Inc, New York City, NY, USA.

[11 ] Department of Oncology, Lekarska fakulta Univerzity Palackeho a Fakultni nemocnice, Olomouc, Czech Republic.

[12 ] Head and Neck Oncology Division, Japanese National Cancer Center, Chiba, Japan.

Article

Publisher Item ID: S1368-8375(21)00015-4

DOI: 10.1016/j.oraloncology.2021.105192

PubMed ID: 33571736

SO-VID: 6d9fe366-1c20-4c84-bbdf-f607337a1524

History

Keywords: Squamous cell carcinoma,Palbociclib,Head and neck cancer,Cetuximab

Data availability:

Keywords: Squamous cell carcinoma, Palbociclib, Head and neck cancer, Cetuximab

Comments

Comment on this article

scite_

Cited by 5

See all cited by